Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.
• 18 years of age or older.
• Any patient that has an untreated primary solid malignancy within the following cohorts:
‣ Breast cancer
⁃ Lung cancer
⁃ Muscle invasive bladder cancer
⁃ Rectal cancer
⁃ Pancreatic cancer
⁃ Ovarian cancer
⁃ Gastroesophageal cancer
⁃ Prostate cancer
⁃ Melanoma
‣ Hepatic/liver cancer
‣ Uterine/endometrial cancer
‣ Head and neck Cancer
• The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging.
• Eastern Cooperative Oncology Group performance status ≤ 2.
• Able to tolerate venipuncture for research blood draw(s).
• Consent to provide residual tumor tissue for research.
• Willing and able to comply with the study requirements.
• Signed informed consent(s) must be obtained prior to participation in the study.